Posted by Michael Wonder on 16 Jul 2021
FDA approves belumosudil for chronic graft versus host disease
16 July 2021 - On 16 July 2021, the FDA approved belumosudil (Rezurock, Kadmon Pharmaceuticals), a kinase inhibitor, for adult and paediatric patients 12 years and older with chronic graft-versus-host disease after failure of at least two prior lines of systemic therapy.
Efficacy was evaluated in KD025-213, a randomised, open-label, multicenter dose-ranging trial that included 65 patients with chronic GVHD who were treated with belumosudil 200 mg taken orally once daily.
